Drug
Phenoxodiol clinical trials
- studies test it
- 10
- open now
- 0
- in phase 3
- 1
- first study started
- 2001
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2017 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 3
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 1
Noxopharm Limited (6) · MEI Pharma, Inc. (2) · Kazia Therapeutics Limited (1) · Royal North Shore Hospital (1)
Often tested with
Tested in the same studies.
Idronoxil Suppository NOX66 (6) · Carboplatin (1) · Doxorubicin (1)
Studies
Open first, then newest update. How each study uses phenoxodiol is read from its arms, and is right about nine times in ten.
Testing it · 10
- Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate CancerCompletedPhase 1Noxopharm LimitedNCT03307629Written as NOX66
- A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue SarcomaTerminatedPhase 1Noxopharm LimitedNCT05100628Written as NOX66
- A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid TumorsTerminatedPhase 1/2Noxopharm LimitedNCT04957290Written as NOX66
- Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate CancerTerminatedPhase 1Royal North Shore HospitalNCT03041285Written as idronoxil (NOX66) suppository
- A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19CompletedPhase 1Noxopharm LimitedNCT04555213Written as NOX66
- Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid TumoursCompletedPhase 1/2Noxopharm LimitedNCT02941523Written as NOX66
- A Study of Safety and Tolerability of NOX66 in Healthy VolunteersWithdrawnPhase 1Noxopharm LimitedNCT03780465Written as Oral idronoxil suspension
- OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian CancerCompletedPhase 3MEI Pharma, Inc.NCT00382811Written as phenoxodiol
- Phenoxodiol in Treating Patients With Refractory Solid TumorsCompletedPhase 1Kazia Therapeutics LimitedNCT00022295Written as idronoxil
- A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate CancerCompletedPhase 2MEI Pharma, Inc.NCT00557037Written as Phenoxodiol
Given in every arm · 2 — phenoxodiol is usual care beside what is tested
- Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity CancerTerminatedPhase 1Yale UniversityNCT00303888Written as idronoxil
- Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedPhase 1/2MEI Pharma, Inc.NCT00091377Written as phenoxodiol
Codes
What other systems call phenoxodiol · ClinicalTrials.gg INT004507
- MeSH (NLM) C471183phenoxodiolOne source NLM
- UNII (FDA) 995FT1W541IDRONOXILConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C471183 | phenoxodiol | One source NLM |
| UNII (FDA) | 995FT1W541 | IDRONOXIL | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.